FARMINGDALE, N.Y., Oct. 30, 2014 /PRNewswire/
-- Misonix, Inc. (NASDAQ: MSON), an international
ultrasonic surgical device company that designs, manufactures and
markets innovative therapeutic ultrasonic instruments for spine
surgery, neurosurgery and other surgical specialties, announced
today that it will report financial results for the first quarter
fiscal year 2015 on Thursday, November 6,
2014. The Company has scheduled a conference call that same
day, Thursday, November 6, 2014, at
4:30 pm ET to review the results.
Interested parties can access the conference call by dialing
(877) 317-6789 or (412) 317-6789 or can listen via a live Internet
webcast, which is available in the Investor Relations section of
the Company's website at www.misonix.com.
A teleconference replay of the call will be available for three
days at (877) 344-7529 or (412) 317-0088, confirmation # 10055534.
A webcast replay will be available in the Investor Relations
section of the Company's website at www.misonix.com for 30
days.
About Misonix
Misonix, Inc. designs, develops, manufactures and markets
therapeutic ultrasonic medical devices. Misonix's therapeutic
ultrasonic platform is the basis for several innovative medical
technologies. Addressing a combined market estimated to be in
excess of $3 billion annually;
Misonix's proprietary ultrasonic medical devices are used in spine
surgery, neurosurgery, orthopedic surgery, wound
debridement, cosmetic surgery, laparoscopic surgery, and other
surgical and medical applications. Additional information is
available on the Company's Web site at www.misonix.com.
Safe Harbor Statement
With the exception of historical information contained in
this press release, content herein may contain "forward looking
statements" that are made pursuant to the Safe Harbor Provisions of
the Private Securities Litigation Reform Act of 1995. These
statements are based on management's current expectations and are
subject to uncertainty and changes in circumstances. Investors are
cautioned that forward-looking statements involve risks and
uncertainties that could cause actual results to differ materially
from the statements made. These factors include general economic
conditions, delays and risks associated with the performance of
contracts, risks associated with international sales and currency
fluctuations, uncertainties as a result of research and
development, acceptable results from clinical studies, including
publication of results and patient/procedure data with varying
levels of statistical relevancy, risks involved in introducing and
marketing new products, potential acquisitions, consumer and
industry acceptance, litigation and/or court proceedings, including
the timing and monetary requirements of such activities, the timing
of finding strategic partners and implementing such relationships,
regulatory risks including approval of pending and/or contemplated
510(k) filings, the ability to achieve and maintain profitability
in the Company's business lines, and other factors discussed in the
Company's Annual Report on Form 10-K, subsequent Quarterly Reports
on Form 10-Q and Current Reports on Form 8-K. The Company disclaims
any obligation to update its forward-looking relationships.
Company
Contact:
|
Investor
Contacts:
|
Richard
Zaremba
|
Robert Blum, Joe
Dorame, Joe Diaz
|
Misonix,
Inc.
|
Lytham Partners,
LLC
|
631-694-9555
|
602-889-9700
|
invest@misonix.com
|
mson@lythampartners.com
|
www.misonix.com
|
www.lythampartners.com
|
SOURCE Misonix, Inc.